---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-26-000003"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2026-02-10T23:59:59+00:00"
generated_at: "2026-05-16T03:34:13.171994+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# iBio reports Q2 FY2026 operating loss; secures $26M PIPE financing led by Frazier Life Sciences

## Summary
- No revenue for Q2 ended Dec 31, 2025, vs $0.2M a year ago; R&D expense $4.3M, G&A $5.2M (includes impairment of IBIO-101 intangible).
- Cash and investments of $52.7M at Dec 31, 2025; net proceeds of ~$24.4M from January PIPE extend runway into Q3 FY2028.
- IBIO-600 (myostatin antibody) on track for Phase 1a clinical trial in H1 2026; IBIO-610 (activin E) aims for first human trials early 2027.
- NHP data for IBIO-610 shows predicted human half-life up to 100 days, supporting twice-yearly dosing.

## SEC filing metadata
- accession: 0001420720-26-000003
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2026-02-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072026000003/0001420720-26-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072026000003/ibio-20260210x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-26-000003
- JSON: https://secwatch.observer/filing/0001420720-26-000003.json
- Plain text: https://secwatch.observer/filing/0001420720-26-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.